These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 17700241)

  • 1. Estimating the effects of time-varying treatments: incidence of fractures among postmenopausal Japanese women.
    Tanaka S; Matsuyama Y; Shiraki M; Ohashi Y
    Epidemiology; 2007 Sep; 18(5):529-36. PubMed ID: 17700241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteodensitometry in healthy postmenopausal women.
    Prescrire Int; 2008 Apr; 17(94):68-72. PubMed ID: 18536138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonate dose and incidence of fractures in postmenopausal osteoporosis.
    Makras P; Hamdy NA; Zwinderman AH; Ballieux BE; Papapoulos SE
    Bone; 2009 May; 44(5):766-71. PubMed ID: 19442613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Postmenopausal osteoporosis].
    László A
    Orv Hetil; 2004 Jan; 145(1):3-13. PubMed ID: 15222134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low bone mineral density and fracture burden in postmenopausal women.
    Cranney A; Jamal SA; Tsang JF; Josse RG; Leslie WD
    CMAJ; 2007 Sep; 177(6):575-80. PubMed ID: 17846439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
    Woodis CB
    Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Estrogen therapy in women with postmenopausal osteoporosis].
    Zarcone R; Carfora E; Sergio F; Bellini P; Longo M; Tartaglia E; Tomasillo G
    Minerva Ginecol; 1997; 49(7-8):355-9. PubMed ID: 9380298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates.
    Earnshaw SR; Graham CN; Ettinger B; Amonkar MM; Lynch NO; Middelhoven H
    Curr Med Res Opin; 2007 Oct; 23(10):2517-29. PubMed ID: 17825128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Current osteoporosis treatment: reasons for adding vitamin D to alendronate].
    Anić B; Grazio S
    Reumatizam; 2006; 53(2):63-5. PubMed ID: 17580557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial.
    Reginster JY; Felsenberg D; Boonen S; Diez-Perez A; Rizzoli R; Brandi ML; Spector TD; Brixen K; Goemaere S; Cormier C; Balogh A; Delmas PD; Meunier PJ
    Arthritis Rheum; 2008 Jun; 58(6):1687-95. PubMed ID: 18512789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary biliary cirrhosis is not an additional risk factor for bone loss in women receiving regular calcium and vitamin D supplementation: a controlled longitudinal study.
    Benetti A; Crosignani A; Varenna M; Giussani CS; Allocca M; Zuin M; Podda M; Battezzati PM
    J Clin Gastroenterol; 2008 Mar; 42(3):306-11. PubMed ID: 18223492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Fracture incidence in 803 women with postmenopausal osteoporosis under drug treatment].
    Cronenberg A; Minkus A; Bremer G; Keck E
    Z Orthop Ihre Grenzgeb; 1993; 131(1):70-4. PubMed ID: 8480444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
    Sethi BK; Chadha M; Modi KD; Kumar KM; Mehrotra R; Sriram U
    J Assoc Physicians India; 2008 Jun; 56():418-24. PubMed ID: 18822620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discontinuity and failures of therapy with bisphosphonates: joint assessment of predictors with multi-state models.
    Zambon A; Baio G; Mazzaglia G; Merlino L; Corrao G
    Pharmacoepidemiol Drug Saf; 2008 Mar; 17(3):260-9. PubMed ID: 18240162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Markov model simulation of the impact of treatment persistence in postmenopausal osteoporosis.
    Cotté FE; Fautrel B; De Pouvourville G
    Med Decis Making; 2009; 29(1):125-39. PubMed ID: 18566486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [How to prevent early postmenopausal fracture risk? Proposition of a strategy].
    Trémollieres F; Pouilles JM; Ribot C
    Gynecol Obstet Fertil; 2009 Jan; 37(1):50-6. PubMed ID: 19110461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Evidence for the selective estrogen receptor modulator raloxifene: its evolving role in the treatment of osteoporosis].
    Ohta H
    Clin Calcium; 2008 Oct; 18(10):1442-50. PubMed ID: 18830041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The potential effects on fracture outcomes of improvements in persistence and compliance with bisphosphonates.
    Rietbrock S; Olson M; van Staa TP
    QJM; 2009 Jan; 102(1):35-42. PubMed ID: 18842684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of osteoporosis with antiresorptive drugs].
    Vestergaard P; Mosekilde L; Brixen K
    Ugeskr Laeger; 2005 Feb; 167(8):883-7. PubMed ID: 15789840
    [No Abstract]   [Full Text] [Related]  

  • 20. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.
    Reid DM; Doughty J; Eastell R; Heys SD; Howell A; McCloskey EV; Powles T; Selby P; Coleman RE
    Cancer Treat Rev; 2008; 34 Suppl 1():S3-18. PubMed ID: 18515009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.